ASMB vs. CPIX, OMER, NKTR, CUE, VTVT, CARM, DERM, CRVS, YS, and ANEB
Should you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Cumberland Pharmaceuticals (CPIX), Omeros (OMER), Nektar Therapeutics (NKTR), Cue Biopharma (CUE), vTv Therapeutics (VTVT), Carisma Therapeutics (CARM), Journey Medical (DERM), Corvus Pharmaceuticals (CRVS), YS Biopharma (YS), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical preparations" industry.
Cumberland Pharmaceuticals (NASDAQ:CPIX) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.
Cumberland Pharmaceuticals has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
Cumberland Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 43.3% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Assembly Biosciences received 54 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 59.21% of users gave Assembly Biosciences an outperform vote while only 45.17% of users gave Cumberland Pharmaceuticals an outperform vote.
In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 38 mentions for Cumberland Pharmaceuticals and 37 mentions for Assembly Biosciences. Cumberland Pharmaceuticals' average media sentiment score of 0.01 beat Assembly Biosciences' score of -0.15 indicating that Assembly Biosciences is being referred to more favorably in the news media.
Assembly Biosciences has a net margin of 0.00% compared to Assembly Biosciences' net margin of -15.87%. Assembly Biosciences' return on equity of 6.84% beat Cumberland Pharmaceuticals' return on equity.
Summary
Assembly Biosciences beats Cumberland Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Assembly Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assembly Biosciences Competitors List
Related Companies and Tools
